You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

chemoradiotherapy

Showing 1 - 25 of 2,322
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined

Not yet recruiting
  • Lung Neoplasms
  • Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
  • Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
  • (no location specified)
Jun 12, 2023

Rectal Cancer Trial (Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Therapy)

Not yet recruiting
  • Rectal Cancer
  • Neoadjuvant Chemoradiotherapy
  • Total Neoadjuvant Therapy
  • (no location specified)
Oct 24, 2023

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
  • Hefei, China
    Anhui provincial hospital
Apr 16, 2023

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical

Recruiting
  • Cervical Cancer
  • +2 more
  • Treatment Group
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 9, 2023

Cervical Cancer Trial (Adebrelimab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Nov 28, 2023

Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Envafolimab and recombinant human endostatin combined with chemoradiotherapy
  • (no location specified)
Sep 23, 2023

Esophageal Carcinoma Trial in Nanjing (Nimotuzumab, Tigio, Concurrent radiation therapy)

Enrolling by invitation
  • Esophageal Carcinoma
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023

Esophageal Cancer, Active Surveillance, Neoadjuvant Chemoradiotherapy Trial in Rotterdam (Active surveillance)

Active, not recruiting
  • Esophageal Cancer
  • +3 more
  • Active surveillance
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC, University Medical Center
Jul 11, 2023

Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Consolidation chemotherapy (4 courses)
  • Concurrent chemotherapy (2 courses)
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Mar 16, 2023

Cervical Cancer Trial (Zimberelimab, Platinum, radiotherapy)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Nov 9, 2023

Rectal Cancer Trial in Chongqing (CIETAI-R)

Recruiting
  • Rectal Cancer
  • CIETAI-R
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
Jul 21, 2023

Cervical Cancer Trial in Heidelberg (MR-guided radiation)

Recruiting
  • Cervical Cancer
  • MR-guided radiation
  • Heidelberg, Germany
    University Hospital of Heidelberg, Radiation Oncology
Nov 15, 2023

Plasma MRD and cfDNA HPV and Efficacy and Prognosis of Locally

Recruiting
  • Locally Advanced Cervical Cancer
  • Concurrent chemoradiotherapy
  • Guiyang, Guizhou, China
    Yong Li
Jul 14, 2023

Stage III NSCLC, Locally Advanced, Unresectable Trial (standard Radiotherapy, Chemotherapy, Immunotherapy)

Not yet recruiting
  • Stage III Non-small Cell Lung Cancer
  • +2 more
  • standard Radiotherapy
  • +3 more
  • (no location specified)
Oct 20, 2023

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023

Esophageal Cancer Trial (Hypofractionated radiotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Hypofractionated radiotherapy
  • (no location specified)
Jan 18, 2023

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced

Not yet recruiting
  • To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
  • Hydrochloride anlotinib
  • +2 more
  • (no location specified)
Mar 6, 2023

Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to

Active, not recruiting
  • Esophageal Cancer
  • follow up
  • Guangzhou, Guangdong, China
    Jianhua Fu
Sep 24, 2023

Uterine Cervical Tumors, Chemoradiotherapy, Adjuvant Chemo Trial in Liuzhou (paclitaxel combined with platinum)

Recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • paclitaxel combined with platinum
  • Liuzhou, Guangxi, China
    the Fourth Affiliated Hospital of Guangxi Medical University
Feb 16, 2023

Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy Trial in Beijing (rhTPO)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • Beijing, Beijing, China
    Department of Radiation Oncology, Cancer Institute and Hospital,
Jul 12, 2023

Dose to Cardiac Substructures on Survival in Esophageal Cancer

Recruiting
  • Esophagus Cancer
    • Brest, France
      Chu Brest
    Aug 16, 2023

    Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

    Not yet recruiting
    • Locally Advanced Rectal Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Aug 5, 2023

    Cervical Cancer Trial in Suzhou (Chemoradiotherapy + Adjuvant chemo and Zimberelimab, Chemoradiotherapy (small pelvic) +

    Recruiting
    • Cervical Cancer
    • Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
    • Chemoradiotherapy (small pelvic) + Zimberelimab
    • Suzhou, Jiangsu, China
      The Affiliated Suzhou Hospital of Nanjing Medical University
    May 14, 2023

    Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinomas
    • +3 more
    • chemotherapy combined with PD-1 inhibitors
    • (no location specified)
    Nov 17, 2022

    Esophageal Cancer Trial in Taoyuan (PET/MRI)

    Completed
    • Esophageal Cancer
    • PET/MRI
    • Taoyuan, Taiwan
      Linkou Chang Gung Memorial Hospital
    May 9, 2023